Side effects were manageable and did not affect the therapeutic benefits for most patients in the analysis, and no treatment-related deaths were reported, according to Wolchok

Kay said that Xofigo is less toxic and has fewer side effects than conventional chemotherapy

Although L-asparaginase has been used to treat ALL for more than 30 years, it has significant side effects, sparking allergic reactions and causing organ damage...Beyen noted that L- asparaginase previously has been tested in pancreatic cancer, but treatment had to be stopped because of side effects.

Although L-asparaginase has been used to treat ALL for more than 30 years, it has significant side effects, sparking allergic reactions and causing organ damage...Beyen noted that L- asparaginase previously has been tested in pancreatic cancer, but treatment had to be stopped because of side effects.

A superior safety profile, including reduced cardiovascular side effects, reduced liver toxicity and fewer off-target side effects, could give RPC1063 the edge against Gilenya

In addition, elobixibat's minimal systemic exposure limits side effects to the gut

The ESP technology can be used to characterize disease profiles, assess preclinical drug efficacy, identify optimal dosing routines or identify undesirable side effects in CNS drugs

clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs

In addition, elobixibat's minimal systemic exposure limits side effects to the gut

Karlsson said the product was designed to circumvent the side effects seen with PDE inhibitors, which in the case of PDE3 include low blood pressure and nausea, and nausea in the case of PDE4...There was no evidence of cardiovascular or gastrointestinal side effects

Serious side effects can include ulcers, altered mental state, seizures, severe skin rashes and allergic reactions...The more favorable dosing regimen of Procysbi, in addition to mitigating gastrointestinal side effects, provides an attractive drug profile

The ESP technology can be used to characterize disease profiles, assess preclinical drug efficacy, identify optimal dosing routines or identify undesirable side effects in CNS drugs

TD-1211, an investigational, once-daily, orally administered, peripherally selective, multivalent inhibitor of the mu opioid receptor designed with a goal of alleviating gastrointestinal side effects of opioid therapy without affecting analgesia, and TD-9855, the lead compound in Theravance's monoamine reuptake inhibitor (MARIN) program in Phase II development for attention-deficit hyperactivity disorder (ADHD) and fibromyalgia

Ligand Pharmaceuticals Inc., of San Diego, reported preclinical data showing highly targeted liver delivery of a clinically active NS5B polymerase inhibitor using the firm's HepDirect technology platform and also demonstrating that HepDirect liver targeting of active nucleosides may be an effective method to improve efficacy while reducing systemic side effects in hepatitis C treatment

LG631-CD34 consists of patients' adult hematopoietic stem cells genetically modified with a lentiviral vector expressing a human MGMT gene variant, which is designed to protect the cells from the toxic side effects of Temodar (temozolomide, Merck & Co. Inc.), a standard-of-care treatment for glioblastoma multiforme

Esperion Therapeutics Inc., of Ann Arbor, Mich., pulled down $33 million in a preferred stock financing for ETC-1002, an oral, once-daily, LDL-C-lowering small-molecule therapy designed to target known lipid and carbohydrate metabolic pathways as a way of knocking down cholesterol while dodging side effects experienced by some users of stents

Phase IIa trials in human subjects were unfortunately halted due to serious side effects attributable to cytotoxic T cells

All other side effects were mild and transient, with no signs of any impact on any hematological parameters or any thrombosis

Nevertheless, Drenth's net conclusion was that "the low incidence of side effects, the relatively short duration of treatment and the pangenotypic properties of the drugs are strong selling points of a sofosbuvir-ribavirin regimen and will probably lower the threshold for HCV treatment for both patients and physicians